Moderna癌症疫苗试验成功股价盘前涨超90%，雅诗兰黛财报超预期

Moderna is the star of the day. The stock is nearly doubling here in the pre-market is up more than 90% and Merck is up about 9%. So there's an experimental mRNA based vaccine from both Moderna and Merck, and it's succeeded in preventing cancer from returning or spreading in high risk melanoma patients. And so this scientists are saying it paves the way for a potentially new life extending treatment for thousands of people diagnosed with the disease.

This is like at least 10,000 people die a year. It's not a small matter. And so Moderna is hoping to have this, uh, cancer vaccine on the market next year. Now, questions still remain about the cost, the feasibility of trying to produce it to scale. Um, the companies will need to prove that the vaccine works in other tumor types, too. Not just melanoma. But this is a huge potential here. And again, it's a double barrel therapy.

It's not one Moderna thing or one Merck thing that the two together. Yeah. With the immunotherapy provided by Merck. Exactly, exactly. So I do okay there. You did great. Like a doctor conversation I don't know I'm out of my league. Let's but this is my leg. Estée Lauder uh, ticker symbol L stock is up 12.5%. As of yesterday's close, it had been down almost 20%. So they own a bunch of beauty brands. Remember when it was just Estée Lauder?

Just yesterday? Lauder, my grandmother's fragrance, her signature fragrance. Well, now they own Mac, Clinique, Smashbox, Jo Malone, you name it. They lost less money than expected last quarter. Net sales climbed more than 6% to 3.6 billion in the fiscal fourth quarter. Their turnaround is picking up steam. A skin care big for them, up 9%. Fragrances continue to be big moneymakers up 10%. Makeup sales bounce back a little bit, up 3%.

But, uh, hair care only up about 7/10 of a percent. They got to work on the hair care. Um, they're continuing to guide for organic net sales growth of 3 to 5% in the coming year, led by fragrance and skincare. Let's not forget to they they had like 10,000 job reductions, some of that through attrition. So they said that also helped. All right. Very good. And uh, La-Z-Boy, the furniture uh company down 17%. Um, and as of yesterday's close, it had been up about 9.5%.

It's one to a loss of more than $2 million. Last quarter, sales fell 3%. Uh, the furniture maker also gave a sales forecast for the current quarter that was below estimates. It's warning that its near-term investments could pressure its margins, things like investing in new stores, uh, advertising some, a digital transformation. I don't know what that means. I imagine has something to do with AI and online. Um, but La-Z-Boy, I mean, it's still a thing, right?

The La-Z-Boy is still a thing. It's still a thing. People love their La-Z-Boy recliners, right? Maybe not as much as they should have last quarter, but they love them.